A Study of TAK-928 in People With Non-Small Cell Lung Cancer

Full Title

A Randomized, Open Label, Multicenter, Phase 3 Trial Evaluating the Efficacy and Safety of TAK-928 Versus Docetaxel in Participants with Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Disease Progression on or after Platinum-Based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy

Purpose

To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.

Contact

For more information or to see if you can join this study, please call Dr. Paul Paik’s office at 646-608-3759.

Protocol
26-328
Phase
Phase III (phase 3)
Investigator
Paul K. Paik
Co-Investigators
Mark Awad
Diseases
Lung Cancer › Lung Cancer, Non-Small Cell
Locations
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Commack Nonna’s Garden Foundation Center
Memorial Sloan Kettering Basking Ridge
Memorial Sloan Kettering Westchester
Memorial Sloan Kettering Monmouth
Memorial Sloan Kettering Bergen
Memorial Sloan Kettering Nassau
ClinicalTrials.gov ID
NCT07217301
ClinicalTrials.gov
Visit ClinicalTrials.gov for full clinical trial description